Annual Report and Form 20-F Information

The report describes AstraZeneca's transformational 2021, marked by completion of the Alexion acquisition and expansion of the Group's rare disease platform. It highlights the Ambition Zero Carbon programme, including targets to reduce operational emissions by 98% by 2026 and the value-chain footprint by 50% by 2030. The report also presents consolidated 2021 GHG data, including Scope 1, market- and location-based Scope 2, Scope 3 across all 15 categories, and total energy consumption.